Epione Robotic Platform Nabs CE Mark for Lung Tumors
Quantum Surgical says the approval is based on a safety and feasibility study conducted at a leading cancer center in Europe.
Quantum Surgical, a French medical robotics company, recently announced it has obtained expanded CE mark approval for its Epione robotic platform in the treatment of lung tumors. Epione is a robotic-assisted percutaneous ablation system that uses a robotic arm, a navigation system, and camera as an alternative to surgery in which a needle is inserted through the skin to the tumor to destroy it. This, according to the company, makes it possible to treat particularly difficult to reach tumors, whether that be due to their size or location.
“The CE mark approval proves the relevance and effectiveness of Epione, which will enable us to offer innovative, targeted, and less invasive treatments to new patients,” said Laetitia Messner, clinical director of Quantum Surgical, in a press release.
Along with its new CE mark for lung tumors, the robotic platform can also be used to treat abdominal tumors like in the liver, kidneys, and pancreas. The new indication is based on a study conducted at Gustave Roussy evaluating the safety and efficacy of Epione to treat lung tumors.